Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Targeted therapies take aim against lung cancer and melanoma.

Mitka M.

JAMA. 2010 Aug 11;304(6):624-6. doi: 10.1001/jama.2010.1055. No abstract available.

PMID:
20699448
2.

PD-1 Blockers.

Wolchok JD.

Cell. 2015 Aug 27;162(5):937. doi: 10.1016/j.cell.2015.07.045.

3.

Addendum: Nivolumab (Opdivo) for metastatic melanoma and metastatic NSCLC.

[No authors listed]

Med Lett Drugs Ther. 2015 Jun 22;57(1471):94. No abstract available.

PMID:
26079767
4.

[Melanoma: a new therapeutic era].

Berthod G, Homicsko K, Bouchaab H, Matter M, Cerottini JP, Guggisberg D, Speiser D, Leyvraz S, Michielin O.

Rev Med Suisse. 2011 May 25;7(296):1126-30. Review. French.

PMID:
21721201
5.

New therapeutic options in systemic treatment of advanced cutaneous melanoma.

Mackiewicz-Wysocka M, Zolnierek J, Wysocki PJ.

Expert Opin Investig Drugs. 2013 Feb;22(2):181-90. doi: 10.1517/13543784.2013.748032. Epub 2012 Dec 8. Review.

PMID:
23215674
6.

[Molecular target therapies for skin cancers].

Uhara H.

Nihon Rinsho. 2015 Aug;73(8):1391-7. Review. Japanese.

PMID:
26281695
7.

Nivolumab (Opdivo) for metastatic melanoma and metastatic NSCLC.

[No authors listed]

Med Lett Drugs Ther. 2015 Jun 8;57(1470):85-7, 94. Review. No abstract available.

PMID:
26035747
8.

Developing targeted therapies for lung cancer.

Gandara DR.

Clin Adv Hematol Oncol. 2003 Nov;1(11):648-9, 690. No abstract available.

PMID:
16258461
9.

[Vepesid and medroxyprogesterone in the treatment of disseminated malignant melanoma].

Pawlicki M, Rolski J, Budzanowska E.

Nowotwory. 1988 Oct-Dec;38(4):267-73. Polish. No abstract available.

PMID:
3075994
10.

PD-L1 expression as a potential predictive biomarker.

Fusi A, Festino L, Botti G, Masucci G, Melero I, Lorigan P, Ascierto PA.

Lancet Oncol. 2015 Oct;16(13):1285-7. doi: 10.1016/S1470-2045(15)00307-1. No abstract available.

PMID:
26433815
11.

New molecular targets in melanoma.

Flaherty KT.

Curr Opin Oncol. 2004 Mar;16(2):150-4. Review.

PMID:
15075908
12.

[Nivolumab for metastatic melanoma-basic knowledge and clinical data].

Yamazaki N, Maeda Y.

Gan To Kagaku Ryoho. 2015 Apr;42(4):434-8. Japanese. No abstract available.

PMID:
26020984
13.

Searching for the Achilles' heel of melanoma cells: new treatment modalities.

Melnikova VO, Bar-Eli M.

Pigment Cell Melanoma Res. 2008 Oct;21(5):505-6. doi: 10.1111/j.1755-148X.2008.00493.x. Epub 2007 Aug 15. No abstract available.

PMID:
18713130
14.

The place of PD-1 inhibitors in melanoma management.

Bowyer S, Lorigan P.

Lancet Oncol. 2015 Aug;16(8):873-4. doi: 10.1016/S1470-2045(15)00094-7. Epub 2015 Jun 23. No abstract available.

PMID:
26115798
15.

Targeting the epidermal growth factor receptor a new strategy in cancer treatment.

Gianni L, Grasselli G.

Suppl Tumori. 2002 Jul-Aug;1(4):S60-1. Review. No abstract available.

PMID:
12415824
16.

Nivolumab success in untreated metastatic melanoma.

Wilkinson E.

Lancet Oncol. 2015 Jan;16(1):e9. doi: 10.1016/S1470-2045(14)71129-5. Epub 2014 Nov 21. No abstract available.

PMID:
25638562
17.

Ipilimumab for advanced metastatic melanoma.

Starz H.

Expert Opin Biol Ther. 2012 Aug;12(8):981-2. doi: 10.1517/14712598.2012.697150. Epub 2012 Jun 13. No abstract available.

PMID:
22690756
18.

Malignant melanoma: advances in diagnosis, prognosis, and treatment.

Krathen M.

Semin Cutan Med Surg. 2012 Mar;31(1):45-9. doi: 10.1016/j.sder.2011.11.006. Review.

PMID:
22361289
19.

Melanoma Treatments: Advances and Mechanisms.

Marzuka A, Huang L, Theodosakis N, Bosenberg M.

J Cell Physiol. 2015 Nov;230(11):2626-33. doi: 10.1002/jcp.25019. Review.

PMID:
25899612
20.

Ipilimumab in patients with melanoma and brain metastases.

Nieder C.

Lancet Oncol. 2012 Jul;13(7):e277; author reply e277-8. doi: 10.1016/S1470-2045(12)70303-0. Epub 2012 Jun 28. No abstract available.

PMID:
22748259

Supplemental Content

Support Center